OTCMKTS:NGSX - NeurogesX Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$0.0050
Today's Range$0.0050 - $0.0050
52-Week Range$0.0025 - $0.0150
VolumeN/A
Average Volume70,548 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pains management therapies to address unmet medical needs. Qutenza is the Company's first commercial product, available in the United States and in certain European countries. Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions and was approved by the food and drugs administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia (PHN). Qutenza is also approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults. The Company's advanced drug candidate is NGX-1998. NGX-1998 is a topical liquid formulation of high concentration capsaicin that the Company is developing to treat neuropathic pain conditions.

Receive NGSX News and Ratings via Email

Sign-up to receive the latest news and ratings for NGSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:NGSX
Previous Symbol
CUSIPN/A
Phone+1-650-3583300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

NeurogesX (OTCMKTS:NGSX) Frequently Asked Questions

What is NeurogesX's stock symbol?

NeurogesX trades on the OTCMKTS under the ticker symbol "NGSX."

Has NeurogesX been receiving favorable news coverage?

Headlines about NGSX stock have trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NeurogesX earned a news impact score of 2.0 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.

How do I buy shares of NeurogesX?

Shares of NGSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeurogesX's official website?

The official website for NeurogesX is http://www.neurogesx.com/.

How can I contact NeurogesX?

NeurogesX's mailing address is 2215 Bridgepointe Pkwy Ste 200, FOSTER CITY, CA 94404-5067, United States. The specialty pharmaceutical company can be reached via phone at +1-650-3583300.


MarketBeat Community Rating for NeurogesX (OTCMKTS NGSX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about NeurogesX and other stocks. Vote "Outperform" if you believe NGSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NGSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel